Aileron Therapeutics Secures $33,000,000 Series E Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=52440910-1047-4ff1-8e08-8b5aff2115b6
Date
10/29/2014
Company Name
Aileron Therapeutics
Mailing Address
281 Albany St. Cambridge, MA 02139 USA
Company Description
Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeuticsfor the treatment of cancer and other diseases.
Website
http://www.aileronrx.com
Transaction Type
Venture Equity
Transaction Amount
$33,000,000
Transaction Round
Series E
Proceeds Purposes
This financing enables Aileron to rapidly move forward the clinical development of ALRN-6924 as well as ongoing translational research.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor